Skip to content
Back to Compounds

Acetyl-L-carnitine

Also called ALCAR, ALC, LAC, acetylcarnitine, acetyl levocarnitine hydrochloride. Carnitine ester (acylcarnitine).

At a glance3 outcomes graded

  • Mood, Benefit foundEvidence maturity: Emerging
  • Global cognition, No effect foundEvidence maturity: Established
  • Mental fatigue, No effect foundEvidence maturity: Emerging
Safety notes
Evidence last reviewed Added to the site , updated 18 studies citedEditorial review: NootropicsWork Editorial TeamEducational, not medical advice
Skeletal structure of acetyl-L-carnitineOO−OON+
Skeletal structure of acetyl-L-carnitine.C9H17NO4Structure: PubChem CID 7045767, National Center for Biotechnology Information

Safety notes

Sources report interactions with medicines.

Read safety and interactions

Bottom line

Acetyl-L-carnitine is a form of carnitine studied mainly in older adults and clinical groups [1][6][9][13]. One team's small trials reported lower fatigue scores, but the evidence is very low quality [9][11][12]. Reviews of clinical groups reported lower mood-symptom scores [6][7], larger dementia trials found no slowing of decline [3][4], and one chemotherapy trial found more nerve symptoms [13].

Key takeaways

  • Almost all controlled trials were in older adults or people with a diagnosed condition; the one study of cognition in healthy adults was an uncontrolled pilot of 17 people [17].
  • In people with Alzheimer's disease, a Cochrane review of 11 trials found no evidence of benefit on objective cognitive measures, and two 1-year trials (431 and 229 patients) found no slowing of decline [2][3][4].
  • Two trials from one research team reported lower mental-fatigue scores in older or clinical groups; a 2019 Cochrane review found fatigue data from only one of those trials, rated it very low quality and judged the effects uncertain [9][11][12].
  • A meta-analysis pooling nine trials in mostly clinical populations against placebo or no treatment reported fewer depressive symptoms, with high heterogeneity [6].
  • In a 24-week trial in 409 women receiving taxane chemotherapy, acetyl-L-carnitine increased nerve symptoms compared with placebo, and a follow-up found them worse overall across two years [13][20].

New to Acetyl-L-carnitine? Start with What is acetyl-L-carnitine? A plain-English guide.

Evidence by outcome

Mood

C, limited. Benefit foundEvidence maturity: Emerging

3 studies linked
Why C, and history for Mood

Two meta-analyses (12 RCTs, 791 participants, nine pooled against placebo or no intervention; 15 studies, 809 participants) report fewer depressive symptoms than placebo, with high heterogeneity (I-squared 86%) in the 2018 analysis, and both call for larger trials. All populations were clinical, so the finding does not transfer to mood in healthy adults. A meta-analysis that mostly pools clinical populations does not count toward B for healthy adults, and clinical-only evidence caps the grade at C.

Rubric condition met: Meta-analyses exist but only in clinical populations (mostly diagnosed depressive and dysthymic disorders), extrapolated to healthy adults; pooled placebo comparison highly heterogeneous

Grade history

  • : Graded C (awaiting approval)
  • : C to C (awaiting approval). Maturity, bias summary and re-check date added
  • : C to C (approved). Editor sign-off November 16, 2026: grade matches the editor-approved final page

Studies and full rationale for Mood

How sure are we? Mood

Evidence maturity: Emerging Meta-analyses exist (12 RCTs, 791 participants; 15 studies, 809 participants), but no preregistered independent trial was confirmed; the population is diagnosed depressive disorders.

Tested as: Acetyl-L-carnitine

Who paid for the studies
Mostly independent
Risk of bias
Not assessed
Trial registry check
Not checked yet
Publication bias
None found. Funnel-plot results not reported in the abstracts read; B3 not assessed.
Outcome measured
A test score, rating scale or performance measure
Who was studied
Clinical populations only
Rules applied
Population cap (logged, no further change): Mostly diagnosed depressive disorders
  • Could rise: Would move to B for the clinical population if a preregistered, independent RCT were positive on its primary outcome. For healthy adults, any controlled trial is needed first.
  • Could fall: Would move to C none if a preregistered RCT of adequate size in diagnosed depression were null.

Science is provisional. This grade reflects the evidence we found as of . Next review: .

Global cognition

C, limited. No effect foundEvidence maturity: Established

6 studies linked
Why C, and history for Global cognition

All controlled evidence is in people with mild cognitive impairment or Alzheimer's disease. A 2003 meta-analysis found a small advantage over placebo (ES 0.201), but a 2003 Cochrane review of 11 trials found no evidence of benefit on objective cognitive measures, and two 1-year trials (431 and 229 patients) found no slowing of decline. The only healthy-adult data found is an uncontrolled pilot of 17 young adults. Direction is none because the larger trials were null. N is not available without adequate RCTs in the relevant population, so the grade is C with direction none, read as limited and mixed.

Rubric condition met: Results only in clinical/older populations (mild cognitive impairment, Alzheimer's disease) being extrapolated to healthy adults

Grade history

  • : Graded C (awaiting approval)
  • : C to C (awaiting approval). Maturity, bias summary and re-check date added
  • : C to C (approved). Editor sign-off November 16, 2026: grade matches the editor-approved final page

Studies and full rationale for Global cognition

How sure are we? Global cognition

Evidence maturity: Established A meta-analysis of more than 5 RCTs from more than one group in people with MCI or Alzheimer's disease (clinical population). The trials predate routine registration, so preregistration is unconfirmed; the C comes from the population cap.

Tested as: Acetyl-L-carnitine

Who paid for the studies
Not stated (treated as not independent)
Risk of bias
Some concerns. One 1-year trial lists two Sigma-Tau authors; others do not state funding.
Trial registry check
Not checked yet
Outcome measured
A test score, rating scale or performance measure
Who was studied
Clinical populations only
Doses used in studies
1.5-3.0 g a day
Rules applied
Population cap (logged, no further change): Clinical populations only
  • Could rise: Would move to C benefit for healthy adults only with a preregistered RCT of at least 100 healthy adults positive on a prespecified cognitive primary outcome.
  • Could fall: Would move to N (clinical population) if a new meta-analysis restricted to placebo-controlled trials were null on objective cognition.

Science is provisional. This grade reflects the evidence we found as of . Next review: .

Mental fatigue

C, limited. No effect foundEvidence maturity: Emerging

4 studies linkedSingle research groupSubjective outcome only
Why C, and history for Mental fatigue

Controlled trials in adults over 70 with fatigue (96 participants; the abstract does not describe the comparison group) and in hepatic encephalopathy (121 patients) reported lower mental-fatigue scores, but every fatigue trial found shares the same research team (Malaguarnera M is an author on each). The only fatigue data in the 2019 Cochrane review of that team's hepatic encephalopathy trials come from the same 121-patient trial [11], re-analyzed; the review rated it very low quality and judged the effects uncertain. No trials in healthy adults were found. Both positive trials come from one team at high risk of bias, and the outcomes are self-reported, so direction is none (limited, mixed), not benefit.

Rubric condition met: Small RCTs only in clinical/older populations (adults over 70 with fatigue; hepatic encephalopathy) extrapolated to healthy adults

Grade history

  • : Graded C (awaiting approval)
  • : C to C (awaiting approval)
  • : C to C (awaiting approval). Maturity, bias summary and re-check date added
  • : C to C (approved). Editor sign-off November 16, 2026: grade matches the editor-approved final page

Studies and full rationale for Mental fatigue

How sure are we? Mental fatigue

Evidence maturity: Emerging Every supporting fatigue trial comes from one research group, so the replication rule holds it at Emerging.

Tested as: Acetyl-L-carnitine

Who paid for the studies
Not stated (treated as not independent)
Risk of bias
High. Cochrane rated the group's trials high risk of bias, underpowered and very low quality.
Trial registry check
Not checked yet
Outcome measured
A test score, rating scale or performance measure
Who was studied
Clinical populations only
Doses used in studies
1.5 g a day or more
Rules applied
B1: risk of bias (logged, no further change): Over half the supporting studies are high risk of bias; step stops at C; B2: one funder or group (logged, no further change): Every supporting trial shares one research group
  • Could rise: Would move to C benefit with an independent, preregistered RCT of at least 100 adults positive on a fatigue primary outcome; to B with two such trials.
  • Could fall: Stays at C none unless two adequately sized independent RCTs are null, which would support N.

Science is provisional. This grade reflects the evidence we found as of . Next review: .

Maturity sits beside each grade. The grade says what the evidence shows; maturity says how much of it there is and how well it is confirmed.

Established
many trials from several independent teams, including at least one registered in advance
Emerging
two or more trials, or one large registered trial, not yet independently confirmed
Early signal
one trial, small pilots, or results only on secondary outcomes
Mechanistic only
lab, animal or biomarker data, or uncontrolled reports; no controlled human results
Traditional use only
a traditional-use monograph and nothing else

Grades describe evidence for each outcome, not a recommendation. Open “Why” on a card for its rationale and dated grade history. How we grade

Almost every controlled trial we found was run in older adults or in people with a diagnosed condition. That matters for anyone reading this page as a healthy adult: as of November 11, 2026 we found no randomized placebo-controlled trials of acetyl-L-carnitine on cognition, mood or fatigue in healthy adults (PubMed and Europe PMC search, November 11, 2026). The one study in healthy people we found was a pilot in 17 young adults aged 22 to 27, with an untreated control group for only one test [17].

Does acetyl-L-carnitine improve memory and cognitive function?

Evidence is mixed, and all of it comes from people with mild cognitive impairment or Alzheimer's disease, a clinical population; results may not apply to healthy adults.

The more favorable synthesis is a 2003 meta-analysis (a study that pools the results of several trials) of double-blind, placebo-controlled trials lasting at least 3 months in people with mild cognitive impairment or mild Alzheimer's disease [1]. Compared with placebo, acetyl-L-carnitine showed a small advantage on an integrated summary of clinical and psychometric tests (effect size 0.201, 95% confidence interval 0.107-0.295) [1]. Its funding is not stated in the PubMed record, and the abstract does not give the number of trials or participants [1].

The Cochrane review published the same year reached a more cautious reading. It included 11 trials, all limited to people with Alzheimer's disease [2]. It found a benefit on one measure, the number of people rated as improved on the clinician's global impression at 12 and 24 weeks (but not at 52 weeks), and no evidence of benefit on cognition, severity of dementia, daily function, or the global impression scored as a continuous measure [2]. The reviewers warned that, given the large number of comparisons made, the significant result may be due to chance [2].

The two largest individual trials point the same way as the Cochrane review. In a 1-year trial, 431 patients aged 50 or older with mild to moderate Alzheimer's disease took 3 g a day or placebo, and both groups declined at the same rate on all primary and most secondary measures [3]. A follow-up 1-year trial of 229 patients aged 45 to 65 with early-onset Alzheimer's disease found that acetyl-L-carnitine failed to slow decline [4]. Funding is not stated in the PubMed records of either trial, and two of the four authors of the 2000 trial listed the drug company Sigma-Tau Pharmaceuticals as their affiliation (Crossref record of the article) [4].

The two reviews differ in who they included (the meta-analysis added people with mild cognitive impairment) and in how outcomes were combined, and the Cochrane authors note that earlier and later trials used very different methods [1][2]. The more conservative reading is the Cochrane one.

For healthy adults, the only data we have is from the pilot study in 17 young adults who received 1.5 g/day for 1 month (not randomized or placebo controlled) [17]. This pilot cannot show effects in healthy people. For a broader overview, see our pages on memory and healthy brain aging.

Does acetyl-L-carnitine reduce mental fatigue?

Two controlled trials in clinical or older groups reported lower mental-fatigue scores, but the evidence base is small, comes from one research team, and relies on questionnaire scores; results may not apply to healthy adults.

In a trial of 96 adults over 70 (age range 71-88) who met criteria for chronic fatigue, indexed in PubMed as a randomized controlled trial, mental-fatigue scores fell by 3.3 points with acetyl-L-carnitine against a rise of 0.6 in the comparison group [9]. The abstract does not describe the comparison group, the dose or the duration [9].

In 121 patients with cirrhosis and overt hepatic encephalopathy (a brain complication of liver disease, a clinical population), 2 g taken twice a day for 90 days improved mental-fatigue scores in the milder group compared with placebo (-1.7 compared with -0.3) [11]. A trial in 92 prefrail older adults, using 1.5 g twice a day for 3 months, reported increases in Mini-Mental State Examination score and walking distance compared with placebo [10]. Its abstract calls the study both randomized and observational, which leaves its design unclear [10].

All three trials share an author and research team (Malaguarnera M is an author on each) [9][10][11]. A 2019 Cochrane review of that team's five trials in liver disease, with 398 participants, noted that all were conducted in Italy by a single team, all were at high risk of bias and underpowered, and all of the evidence was very low quality [12]. Its fatigue data came from a single trial, the 121-patient trial above; the review judged the effects uncertain and the evidence very low quality [12]. The Cochrane authors also noted that none of those trials was sponsored by the pharmaceutical industry [12].

As noted at the start of this section, we found no placebo-controlled fatigue trials in healthy adults. Our mental energy and fatigue page covers compounds with trials in healthy people.

Does acetyl-L-carnitine affect mood?

Meta-analyses report fewer depressive symptoms than placebo, but only in clinical populations, mostly people with diagnosed mood disorders, and the pooled results vary widely between trials; results may not apply to healthy adults.

A 2018 meta-analysis included 12 randomized controlled trials with 791 participants (mean age 54 years, 65% female) [6]. Pooling nine trials in these mostly clinical populations, acetyl-L-carnitine reduced depressive symptoms compared with placebo or no intervention (standardized mean difference -1.10, 95% CI -1.65 to -0.56) [6]. Heterogeneity was high (I-squared 86%), meaning the trials disagreed a good deal about the size of the effect [6]. In three trials in the same kind of population that compared it with established antidepressants, symptom changes were similar and adverse effects were less frequent with acetyl-L-carnitine [6]. Those comparisons involved people with diagnosed depressive disorders; they do not show that it can stand in for prescribed medicine [6]. Subgroup analyses suggested the largest effect in older adults, and the authors called for large trials to confirm or refute the findings [6].

A 2026 synthesis of 15 studies (14 randomized trials and one open-label study) with 809 participants with major depressive or bipolar disorder reached a similar conclusion against placebo and also called for larger, longer studies [7]. Several of its authors list industry advisory roles or grants in the paper's conflict-of-interest statement, some described as outside the submitted work [7].

Among the individual trials, a 7-week double-blind study in 80 older adults with diagnosed dysthymic disorder (long-lasting low mood) found results equivalent to a prescription antidepressant; it had no placebo arm [8]. For the wider mood evidence, see our mood and stress page.

What the evidence does not show

The trials summarized here do not show effects in healthy adults on memory, attention, mental fatigue or mood (see the dated search note at the start of this section).

They also do not show that it slows decline in Alzheimer's disease; a post hoc age pattern in the earlier 1-year trial was not confirmed by the later trial designed to test it [3][4].

Doses used in studies

Ranges researchers used, not dosing advice. Bars share one scale. Read our disclaimer.

Mild cognitive impairment and mild Alzheimer's disease (meta-analysis)1.5-3.0 g/day for 3, 6 or 12 months1.5 to 3 g
Alzheimer's disease (1-year trials)3 g/day (1 g three times a day) for 12 months3 g
Prefrail older adults1.5 g twice a day for 3 months1.5 g
Hepatic encephalopathy (fatigue)2 g twice a day for 90 days2 g
Taxane chemotherapy (safety signal)3,000 mg per day for 24 weeks

3,000 mg per day for 24 weeks

Healthy young adults (uncontrolled pilot)1.5 g daily for 1 month1.5 g
Healthy volunteers (pharmacokinetics)single doses of 0.5 or 1.5 g1.5 g

Timing and form

Absorption appears to be low. In a 2025 study in healthy volunteers given 0.5 or 1.5 g, both acetylcarnitine and carnitine showed low absorption from the gut and low recovery by the kidneys [14]. After a 1.5 g dose, peak blood levels rose 48% above baseline for acetylcarnitine and 43% for carnitine [14]. The increase in total exposure (area under the curve) from acetylcarnitine was 7.7-fold lower than from carnitine, and the acetylcarnitine was mostly eliminated in the form of carnitine [14].

An older review of carnitine kinetics reports that lab experiments suggest acetyl-L-carnitine is partly broken down in the gut lining during absorption [15]. In people taking 2 g a day, blood acetyl-L-carnitine rose 43%, which indicates some is absorbed intact [15].

As of November 11, 2026 we found no oral half-life for acetyl-L-carnitine (PubMed search, November 11, 2026). The NIH Office of Dietary Supplements fact sheet (as archived) notes that the bioavailability of acetyl-L-carnitine has not been well studied [21].

What it is

Acetyl-L-carnitine (often shortened to ALCAR, ALC or LAC) is a form of carnitine: the body's carnitine pool is made up of free L-carnitine and many esters of it, and acetyl-L-carnitine is the main one by amount and function [15].

In Australia it appears in at least one listed medicine with acetyl levocarnitine hydrochloride as the active ingredient [19].

Mechanism, from lab and review work rather than outcome trials: reviewers describe activity at nerve cells that use acetylcholine, membrane stabilization and support for mitochondrial function (the energy-producing parts of cells) [2]. A 2020 review of studies in people with dementia and other cognitive disorders (clinical populations) adds that its role in those groups is still under debate [5]. These mechanisms explain why it has been studied; they do not show that it changes any outcome in people.

Safety and interactions

Safety flag. In a 24-week trial in 409 women receiving taxane chemotherapy, acetyl-L-carnitine increased chemotherapy-induced peripheral neuropathy compared with placebo [13]. A follow-up of the same trial found nerve symptoms were statistically significantly worse overall with acetyl-L-carnitine across two years [20]. Pooled analyses of dementia trials found no statistically significant difference in adverse events between acetyl-L-carnitine and placebo [2]. A Cochrane review judged the harms profile unclear and noted that harms may have been underestimated [12]. The NIH Office of Dietary Supplements fact sheet (as archived) says carnitine has no established tolerable upper intake level, and that doses of about 3 g a day of carnitine supplements can cause nausea, vomiting, abdominal cramps, diarrhea and a fishy body odor [21]. The same fact sheet says carnitine can cause seizures in people with seizure disorders and muscle weakness in people with uremia [21]. As of November 11, 2026, the sources we checked (PubMed and Europe PMC safety searches) do not include a systematic safety review of acetyl-L-carnitine. In healthy volunteers, about 90% of acetylcarnitine and carnitine supplements were metabolized to TMAO, which the authors describe as raising potential health concerns [14].

Who sources say should be careful.

For L-carnitine products, Health Canada's monograph (which also sets a combined limit with acetylcarnitine) requires labels to advise asking a health care practitioner before use if pregnant or breastfeeding, or if the person has a seizure disorder [18]. The monograph does not say whether the same cautions were assessed for acetyl-L-carnitine on its own [18]. The NIH Office of Dietary Supplements fact sheet (as archived), which covers carnitine forms including acetyl-L-carnitine, says carnitine can cause seizures in people with seizure disorders and muscle weakness in people with uremia, a complication of kidney failure [21].

The authors of the chemotherapy trial concluded that patients should be discouraged from using supplements without proven efficacy, after finding more nerve symptoms with acetyl-L-carnitine [13]. People receiving taxane chemotherapy were the group studied in that trial [13].

The trials in Alzheimer's disease and their reviews reported acetyl-L-carnitine as well tolerated, with no statistically significant difference in adverse events from placebo [1][2][3][4].

Those reassurances have limits. The Cochrane review of the liver-disease trials called the harms profile presently unclear, and noted that adverse event data were poorly reported and harms may have been underestimated [12].

The clearest safety signal comes from a trial in a clinical population funded by public research grants, including US National Cancer Institute grants, listed in its PubMed record. In a 24-week double-blind trial, 409 evaluable women receiving taxane-based chemotherapy for breast cancer took 3,000 mg per day or placebo [13]. There was no difference at 12 weeks, but by 24 weeks acetyl-L-carnitine significantly increased chemotherapy-induced peripheral neuropathy, the nerve symptoms the trial set out to reduce [13]. Severe (grade 3 to 4) neurotoxicity was more frequent with acetyl-L-carnitine, eight cases against one [13]. A follow-up of the same 409 women, funded by National Cancer Institute grants, found that nerve symptoms were statistically significantly worse overall in the acetyl-L-carnitine group across two years of follow-up [20].

A second question concerns TMAO, a metabolite of carnitine supplements. In the 2025 healthy-volunteer study, about 90% of both acetylcarnitine and carnitine supplements were metabolized to TMAO, and the authors wrote that this substantial TMAO production raises potential health concerns [14]. This is a single absorption study, not an outcome trial.

The NIH Office of Dietary Supplements fact sheet (as archived on November 3, 2026), which covers carnitine forms including acetyl-L-carnitine, says carnitine has no established tolerable upper intake level, and that doses of about 3 g a day of carnitine supplements can cause nausea, vomiting, abdominal cramps, diarrhea and a fishy body odor [21]. Several trials on this page used about that daily amount [3][10][13].

As of November 11, 2026, the sources we checked (PubMed and Europe PMC searches for safety reviews and meta-analyses, run November 11, 2026) do not include a systematic safety review of acetyl-L-carnitine.

Interactions sources report

The sources we reviewed report these findings relevant to people taking medicines.

Chemotherapy medicines, specifically taxanes: as described under Safety, acetyl-L-carnitine increased nerve symptoms in women receiving taxanes [13][20].

Thyroid hormone medicines, such as levothyroxine: a 6-month trial gave 2 or 4 g a day of L-carnitine (not the acetyl form) to 50 women taking a fixed suppressive dose of levothyroxine, based on lab findings that carnitine inhibits thyroid hormone entry into cell nuclei [16]. While the women took L-carnitine, their symptoms and biochemical markers did not worsen or even improved, which suggests carnitine can blunt the effects of thyroid hormone [16]. Whether acetyl-L-carnitine does the same was not tested.

Antibiotics, specifically pivalate-conjugated antibiotics such as pivampicillin: the NIH Office of Dietary Supplements carnitine fact sheet (as archived on November 3, 2026) says carnitine interacts with these antibiotics, and that long-term use of them can lead to carnitine depletion [21].

Anticonvulsant medicines, such as valproic acid, phenobarbital, phenytoin and carbamazepine: the same fact sheet says treatment with these medicines reduces blood levels of carnitine [21].

As of November 11, 2026, the sources we checked (PubMed searches for drug interactions, including with blood thinners and thyroid hormone, run November 11, 2026) do not include an interaction study specific to acetyl-L-carnitine.

If you take any of these medicines, talk to your doctor or pharmacist before combining them with acetyl-L-carnitine.

Products containing it

Partner product: we earn a commission

Qualia Mind 2.0

Contains this compound among other ingredients. Our review compares each dose with the doses used in studies.

Read our review
Where to buy: partner product

Qualia Mind 2.0 contains Acetyl-L-carnitine

Acetyl-L-carnitine is one of 31 ingredient entries on the Qualia Mind 2.0 label. The grades on this page are for Acetyl-L-carnitine on its own, not for the product.

Our Qualia Mind 2.0 review compares each label dose with the doses used in studies.

See Qualia Mind 2.0 at Qualia (affiliate link)

We earn a commission if you buy through this link. It never changes a grade or a verdict. How we make money.

FAQ

What is the difference between ALCAR and L-carnitine?

Acetyl-L-carnitine is an ester of L-carnitine and the main ester in the body's carnitine pool [15]. In a study in healthy volunteers, the rise in blood levels (area under the curve) after an acetylcarnitine supplement was 7.7-fold lower than after carnitine, and the acetylcarnitine was mostly eliminated as carnitine [14].

Does acetyl-L-carnitine help with mental fatigue?

Trials in adults over 70 with fatigue and in people with hepatic encephalopathy, a clinical population, reported lower mental-fatigue scores than comparison groups [9][11]. Both come from one research team. A 2019 Cochrane review found fatigue data from only the 121-patient trial, rated it very low quality and judged the effects uncertain [12]. As of November 11, 2026 we found no randomized placebo-controlled trials of acetyl-L-carnitine on fatigue in healthy adults (PubMed and Europe PMC search, 2026-11-11); results may not apply to healthy adults.

Does acetyl-L-carnitine improve memory?

In people with mild cognitive impairment or mild Alzheimer's disease, a 2003 meta-analysis reported a small advantage over placebo [1], while a Cochrane review found no evidence of benefit on objective cognitive tests [2]. The one study of cognition in healthy young adults was an uncontrolled pilot of 17 people [17].

What doses did studies use?

Trials in clinical and older populations used 1.5 to 4 g a day, up to 2 g twice a day [1][3][10][11]; the table above gives each study's dose. These are doses used in studies, not recommendations.

References

  1. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol. 2003.PMID 12598816DOI 10.1097/00004850-200303000-00001Tier 1, meta-analysis
  2. Hudson S, Tabet N. Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev. 2003.PMID 12804452DOI 10.1002/14651858.CD003158Tier 1, systematic review
  3. Thal LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology. 1996.PMID 8797468DOI 10.1212/wnl.47.3.705Tier 1, RCT
  4. Thal LJ, Calvani M, Amato A, et al. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology. 2000.PMID 10994000DOI 10.1212/wnl.55.6.805Tier 1, RCT
  5. Pennisi M, Lanza G, Cantone M, et al. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. Nutrients. 2020.PMID 32408706DOI 10.3390/nu12051389Tier 1, narrative review
  6. Veronese N, Stubbs B, Solmi M, et al. Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis. Psychosom Med. 2018.PMID 29076953DOI 10.1097/PSY.0000000000000537Tier 1, meta-analysis
  7. Kumar R, Hashempour Z, Shahriarirad S, et al. Current Evidence of Acetyl-L-Carnitine Use in Mood Disorders-: A Systematic Review and Meta-Analysis. Neuropsychiatr Dis Treat. 2026.PMID 42261369DOI 10.2147/NDT.S586506Tier 1, narrative review
  8. Bersani G, Meco G, Denaro A, et al. L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. Eur Neuropsychopharmacol. 2013.PMID 23428336DOI 10.1016/j.euroneuro.2012.11.013Tier 1, RCT
  9. Malaguarnera M, Gargante MP, Cristaldi E, et al. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. Arch Gerontol Geriatr. 2008.PMID 17658628DOI 10.1016/j.archger.2007.03.012Tier 1, RCT
  10. Malaguarnera G, Catania VE, Bertino G, et al. Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A Randomized Interventional Clinical Trial. Curr Pharm Des. 2022.PMID 36043711DOI 10.2174/1381612828666220830092815Tier 1, RCT
  11. Malaguarnera M, Vacante M, Giordano M, et al. Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Am J Clin Nutr. 2011.PMID 21310833DOI 10.3945/ajcn.110.007393Tier 1, RCT
  12. Martí-Carvajal AJ, Gluud C, Arevalo-Rodriguez I, et al. Acetyl-L-carnitine for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2019.PMID 30610762DOI 10.1002/14651858.CD011451.pub2Tier 1, meta-analysis
  13. Hershman DL, Unger JM, Crew KD, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol. 2013.PMID 23733756DOI 10.1200/JCO.2012.44.8738Tier 1, RCT
  14. Krims-Davis K, Ozola M, Razzivina V, et al. Low Bioavailability and High TMAO Production: Novel Insights Into Acetylcarnitine and Carnitine Metabolism. Mol Nutr Food Res. 2025.PMID 41243468DOI 10.1002/mnfr.70316Tier 1, RCT
  15. Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci. 2004.PMID 15591001DOI 10.1196/annals.1320.003Tier 1, narrative review
  16. Benvenga S, Ruggeri RM, Russo A, et al. Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2001.PMID 11502782DOI 10.1210/jcem.86.8.7747Tier 1, RCT
  17. Lino A, Boccia MM, Rusconi AC, et al. [Psycho-functional changes in attention and learning under the action of L-acetylcarnitine in 17 young subjects. A pilot study of its use in mental deterioration]. Clin Ter. 1992.PMID 1638856Tier 1, controlled trial
  18. Health Canada (Natural and Non-prescription Health Products Directorate). Natural Health Products Ingredients Database monograph: L-Carnitine. Updated July 25, 2025.SourceTier 1
  19. Therapeutic Goods Administration (ARTG public summary). Public Summary 311848: Orthoplex Acetyl-L-Carnitine (listed medicine). Updated October 26, 2025.SourceTier 1
  20. Hershman DL, Unger JM, Crew KD, et al. Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). J Natl Cancer Inst. 2018.PMID 29361042DOI 10.1093/jnci/djx259Tier 1, RCT
  21. NIH Office of Dietary Supplements. Carnitine: Fact Sheet for Health Professionals (as archived). Updated April 17, 2023.SourceTier 2
Reviewed by NootropicsWork Editorial Team, editorial team. Checklist logged . Next review due . Report an error